Abstract: The present invention features nucleic acid trans-splicing molecules (e.g., pre-mRNA trans-splicing molecules (RTMs)) capable of correcting one or more mutations in the ABCA4 gene or the CEP290 gene. Such molecules are useful in the treatment of disorders associated with mutations in ABCA4, such as Stargardt Disease (e.g., Stargardt Disease 1) and disorders associated with a mutation in CEP290, such as Leber congenital amourosis 10 (LCA 10). Also provided by the invention described herein are methods of using the nucleic acid trans-splicing molecules for correcting mutations in ABCA4 and CEP290 and for treating disorders associated with mutations in ABCA4 and CEP290, such as Stargardt Disease and LCA 10.

Abstract: An on-chip circuit for protection against electrostatic discharge (ESD) is disclosed. Unlike conventional ESD protection circuit using high turn-on voltage diode string, the circuit uses a plural of enhancement-mode HEMT/MESFET triggered by a shorter diode string to shunt large ESD current for protected susceptive RF circuit. Further, by using dual-gate technology of enhancement-mode HEMT/MESFET, the on-chip ESD protection circuit has the less parasitic capacitance without expanding device size for vulnerable RF circuit.

Abstract: An on-chip circuit for protection against electrostatic discharge (ESD) is disclosed. Unlike conventional ESD protection circuit using high turn-on voltage diode string, the circuit uses a plural of enhancement-mode HEMT/MESFET triggered by a shorter diode string to shunt large ESD current for protected susceptive RF circuit. Further, by using dual-gate technology of enhancement-mode HEMT/MESFET, the on-chip ESD protection circuit has the less parasitic capacitance without expanding device size for vulnerable RF circuit.